表紙：皮膚糸状菌性爪真菌症治療薬市場：北米が世界市場シェアの50%近くを占める見込み

市場調査レポート

商品コード

1077486

皮膚糸状菌性爪真菌症治療薬市場：北米が世界市場シェアの50%近くを占める見込み

Market Study on Dermatophytic Onychomycosis Therapeutics: North America to Account for Close to 50% Global Market Share

出版日: 2022年03月29日 | 発行: Persistence Market Research

| ページ情報: 英文 336 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

Unprintable PDF (Single User License)

USD 4,900 763,665円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピーはできません。PDFの印刷もできません。

PDF (Multi User License)

USD 7,600 1,184,460円

レポートPDFを同一企業内の5名様までご利用頂けるライセンスです。PDF内のテキストの編集が可能です。PDFの印刷は5部までとし、そのご利用はPDFのご利用範囲に準拠します。

PDF (Corporate User License)

USD 10,600 1,652,010円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキストの編集が可能です。印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.85円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の皮膚糸状菌性爪真菌症治療薬市場について調査し、市場の概要とともに、治療別、適応別、性別、年齢層別、流通チャネル別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

イントロダクション/主な調査結果
過去の市場：適応症別
現在および将来の市場分析と予測：適応別
- 遠位爪下爪真菌症
- 白い表在性爪真菌症
- 近位爪下爪真菌症
- カンジダ爪真菌症
- 総ジストロフィー性爪真菌症
市場の魅力分析：適応症別

第11章世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：性別

イントロダクション/主な調査結果
市場実績分析：性別
現在および将来の市場分析と予測：性別
- 男性
- 女性
市場の魅力分析：性別

第12章世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：年齢層別

イントロダクション/主な調査結果
市場実績分析：年齢層別
現在および将来の市場分析と予測：年齢層別
- 0～18歳
- 18～39歳
- 40～64歳
- 65歳以上
市場の魅力分析：性別

第13章世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：流通チャネル別

イントロダクション/主な調査結果
市場実績分析：流通チャネル別
現在および将来の市場分析と予測：流通チャネル別
- 機関投資家向け販売
- 小売売上高
- 通信販売薬局とオンライン販売
市場の魅力分析：性別

第14章世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：地域別

イントロダクション
市場実績分析：地域別
現在の市場分析と予測：地域別
- 北米
- ラテンアメリカ
- 欧州
- 東アジア
- 南アジア
- オセアニア
- 中東・アフリカ
市場の魅力分析：地域別

第15章北米の皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第16章ラテンアメリカの皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第17章欧州の皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第18章南アジアの皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第19章オセアニアの皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第20章中東・アフリカの皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第21章主要および新興国の皮膚糸状菌性爪真菌症治療薬市場分析：2022年および2031年

第22章市場構造分析

第23章競合分析

競合ダッシュボード
競合ベンチマーク
競合動向
- Bausch Health
- Galderma S.A.
- Novartis AG
- Pfizer, Inc.
- Moberg Pharma AB
- Bayer AG
- Dr. Reddy's Laboratories Ltd.
- Cipla Ltd.
- Medimetriks Pharmaceuticals, Inc.
- Sanofi S.A.
- GlaxoSmithKline Plc.
- Teva Pharmaceutical industries Ltd.
- Cardinal Health Inc.
- Viatris Inc.
- Almirall, S.A

第24章使用される仮定と頭字語

第25章調査手法

図表

List of Tables

Table 01: Reimbursement Analysis for Onychomycosis
Table 02: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 03: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 04: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 05: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 06: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 07: Global Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Region
Table 08: North America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 09: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 10: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 11: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 12: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 13: North America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 14: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 15: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 16: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 17: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 18: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 19: Latin America Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 20: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 21: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 22: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 23: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 24: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 25: Europe Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 26: South Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 27: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 28: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 29: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 30: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 31: South Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 32: East Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 33: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 34: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 35: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 36: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 37: East Asia Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 38: Oceania Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 39: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 40: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 41: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 42: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 43: Oceania Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel
Table 44: MEA Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Country
Table 45: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Treatment Type
Table 46: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Indication
Table 47: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Gender
Table 48: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Age Group
Table 49: MEA Dermatophytic Onychomycosis Therapeutics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2031, By Distribution Channel

List of Figures

Figure 01: Global Market Value 2022E
Figure 02: Global Market Share 2022E & 2031F
Figure 03: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Treatment Type, 2022E
Figure 04: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Indication, 2022E
Figure 05: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Gender, 2022E
Figure 06: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Age Group, 2022E
Figure 07: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Distribution Channel, 2022E
Figure 08: Global Dermatophytic Onychomycosis Therapeutics Market Historical Market Value and Y-o-Y, 2013-2021
Figure 09: Global Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 10: Onychomycosis Incidence by Income Group (2022E)
Figure 11: Global Onychomycosis Rate by Age Group (2021)
Figure 12: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Treatment Type, 2022-2031
Figure 13: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Oral Drug Treatment, 2022E
Figure 14: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Topical Drug Treatment, 2022E
Figure 15: Global Dermatophytic Onychomycosis Therapeutics Market Revenue Share by Laser Treatment, 2022E
Figure 16: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment Type, 2022E
Figure 17: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Indication, 2022-2031
Figure 18: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Indication, 2022-2031
Figure 19: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022E
Figure 20: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Gender, 2022-2031
Figure 21: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Gender, 2022-2031
Figure 22: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022E
Figure 23: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Age Group, 2022-2031
Figure 24: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Age Group, 2022-2031
Figure 25: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022E
Figure 26: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Distribution Channel, 2022-2031
Figure 27: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Distribution Channel, 2022-2031
Figure 28: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2022E
Figure 29: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Region, 2022-2031
Figure 30: Global Dermatophytic Onychomycosis Therapeutics Market Y-o-Y Analysis (%), By Region, 2022-2031
Figure 31: Global Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Region, 2022E
Figure 32: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)
Figure 33: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)
Figure 34: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)
Figure 35: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)
Figure 36: North America Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)
Figure 37: North America Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)
Figure 38: North America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016-2022E
Figure 39: North America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 40: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031
Figure 41: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031
Figure 42: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031
Figure 43: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031
Figure 44: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031
Figure 45: North America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031
Figure 46: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)
Figure 47: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)
Figure 48: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)
Figure 49: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)
Figure 50: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)
Figure 51: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)
Figure 52: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016-2022E
Figure 53: Latin America Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 54: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031
Figure 55: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031
Figure 56: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031
Figure 57: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031
Figure 58: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031
Figure 59: Latin America Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031
Figure 60: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)
Figure 61: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)
Figure 62: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)
Figure 63: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)
Figure 64: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)
Figure 65: Europe Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)
Figure 66: Europe Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016-2022E
Figure 67: Europe Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 68: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031
Figure 69: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031
Figure 70: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031
Figure 71: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031
Figure 72: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031
Figure 73: Europe Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031
Figure 74: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)
Figure 75: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)
Figure 76: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)
Figure 77: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)
Figure 78: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)
Figure 79: South Asia Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)
Figure 80: South Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016-2022E
Figure 81: South Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 82: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031
Figure 83: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031
Figure 84: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031
Figure 85: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031
Figure 86: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031
Figure 87: South Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031
Figure 88: Latin America Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)
Figure 89: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)
Figure 90: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)
Figure 91: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)
Figure 92: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)
Figure 93: East Asia Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)
Figure 94: East Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016-2022E
Figure 95: East Asia Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 96: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031
Figure 97: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031
Figure 98: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031
Figure 99: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031
Figure 100: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031
Figure 101: East Asia Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031
Figure 102: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)
Figure 103: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)
Figure 104: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)
Figure 105: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)
Figure 106: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)
Figure 107: Oceania Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)
Figure 108: Oceania Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016-2022E
Figure 109: Oceania Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 110: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031
Figure 111: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031
Figure 112: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031
Figure 113: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031
Figure 114: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031
Figure 115: Oceania Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031
Figure 116: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Country (2022E)
Figure 117: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Treatment (2022E)
Figure 118: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Indication (2022E)
Figure 119: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Gender (2022E)
Figure 120: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By Age Group (2022E)
Figure 121: MEA Dermatophytic Onychomycosis Therapeutics Market Share, By End Users (2022E)
Figure 122: MEA Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) Analysis, 2016-2022E
Figure 123: MEA Dermatophytic Onychomycosis Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2021-2031
Figure 124: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Country, 2022-2031
Figure 125: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Treatment, 2022-2031
Figure 126: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Indication, 2022-2031
Figure 127: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Gender, 2022-2031
Figure 128: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By Age Group, 2022-2031
Figure 129: MEA Dermatophytic Onychomycosis Therapeutics Market Attractiveness Analysis, By End User, 2022-2031
Figure 130: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 131: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 132: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 133: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 134: U.S. Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 135: U.S. Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 136: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 137: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 138: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 139: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 140: Canada Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 141: Canada Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 142: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 143: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 144: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 145: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 146: Brazil Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 147: Brazil Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 148: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 149: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 150: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 151: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 152: Mexico Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 153: Mexico Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 154: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 155: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 156: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 157: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 158: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 159: Argentina Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 160: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 161: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 162: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 163: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 164: Argentina Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 165: Argentina Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 166: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 166: Global Onychomycosis Treatment: Brand Share (2022E)
Figure 167: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 168: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 169: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 170: Germany Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 171: Germany Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 172: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 173: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 174: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 175: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 176: France Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 177: France Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 178: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 179: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 180: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 181: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 182: Spain Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 183: Spain Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 184: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 185: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 186: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 187: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 188: Italy Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 189: Italy Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 190: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 191: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 192: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 193: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 194: U.K Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 195: U.K Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 196: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 197: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 198: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 199: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 200: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 201: Benelux Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 202: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 203: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 204: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 205: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 206: Benelux Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 207: Benelux Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 208: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 209: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 210: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 211: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 212: Nordics Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 213: Nordics Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 214: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 215: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 216: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 217: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 218: Russia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 219: Russia Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 220: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 221: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 222: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 224: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 225: Poland Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 225: Poland Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 226: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 227: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 228: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 229: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 230: India Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 231: India Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 232: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 233: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 234: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 235: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 236: Thailand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 237: Thailand Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 238: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 239: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 240: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 241: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 242: Malaysia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 243: Malaysia Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 244: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 245: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 246: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 247: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 248: Indonesia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 249: Indonesia Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 250: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 251: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 252: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 253: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 254: China Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 255: China Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 256: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 257: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 258: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 259: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 260: Japan Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 261: Japan Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 262: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 263: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 264: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 265: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 266: South Korea Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 267: South Korea Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 268: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 269: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 270: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 271: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 272: Australia Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 273: Australia Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 274: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 275: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 276: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 277: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 278: New Zealand Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 279: New Zealand Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 280: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 281: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 282: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 283: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 284: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 285: GCC Countries Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 286: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Treatment Type, 2022E & 2031
Figure 287: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Indication, 2022E & 2031
Figure 288: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Gender, 2022E & 2031
Figure 289: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by Age, 2022E & 2031
Figure 290: South Africa Dermatophytic Onychomycosis Therapeutics Market Share Analysis (%), by End User, 2022E & 2031
Figure 291: South Africa Dermatophytic Onychomycosis Therapeutics Market Value Analysis (US$ Mn), 2022E & 2031
Figure 292: Global Dermatophytic Onychomycosis Therapeutics Market, Absolute $ Opportunity, 2022E -2030
Figure 293: Global Dermatophytic Onychomycosis Therapeutics Market - Share Analysis (%), By Treatment Type, 2022-2031

Product Code: PMRREP5840

Dermatophytic Onychomycosis Therapeutics Market: Scope of Report

The latest publication by Persistence Market Research on the global dermatophytic onychomycosis therapeutics (DOT) market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2031.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for dermatophytic onychomycosis therapeutics products and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the dermatophytic onychomycosis therapeutics market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the dermatophytic onychomycosis therapeutics market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the dermatophytic onychomycosis therapeutics market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research's study on the DOT market offers information divided into six important segments - treatment type, indication, gender, age group, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Treatment Type

Drugs

Oral

OTC

Topical

OTC

Lasers

C02 Ablative Lasers

Nd:YAG Lasers

Dual-wave Length Near-infrared Lasers

Photodynamic Therapy

Indication

Distal Subungual Onychomycosis

White Superficial Onychomycosis

Proximal Subungual Onychomycosis

Candidal Onychomycosis

Total Dystrophic Onychomycosis

Gender

Male

Female

Age Group

0-18 Years

18-39 Years

40-64 Years

65 Years and Above

Distribution Channel

Institutional Sales

Hospitals

Dermatology Clinics

Retail Sales

Retail Pharmacies

Drug Stores

Mail Order Pharmacies & Online Sales

Region

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East & Africa (MEA)

Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for dermatophytic onchomycosis therapeutics over the coming years?

How will changing trends impact the market?

How has the COVID-19 crisis impacted market growth?

How can market players capture the low-hanging opportunities in developed regions?

What are the strategies of stakeholders in the market to shape their position in this landscape?

What are the restraining factors that investors need to be aware of and might tackle while investing in the market?

What are the developmental trends that will impact the market?

How can companies in the dermatophytic onychomycosis therapeutics industry avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the (DOT market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research's projections on the growth prospects of the dermatophytic onychomycosis therapeutics market are more accurate and reliable.

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Disease Epidemiology
4.2. Treatment Regime (Prescription Pattern)
4.3. Key Regulation Scenario
4.4. Pipeline Analysis
4.5. Reimbursement Scenario

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Per Capita Healthcare Expenditure Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Social Determinants
- 5.2.2. Growing Elderly Population and future Outlook
- 5.2.3. New Market Development For Advanced Products Exhibit Lucrative Growth Opportunities
5.3. Value Chain
5.4. Market Dynamics
- 5.4.1. Drivers
- 5.4.2. Restraints
- 5.4.3. Opportunity Analysis

6. COVID19 - Impact Analysis

6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
- 6.4.1. Revenue By Treatment
- 6.4.2. Revenue By Indication
- 6.4.3. Revenue By Gender
- 6.4.4. Revenue By Age Group
- 6.4.5. Revenue By Distribution Channel
- 6.4.6. Revenue By Country
6.5. Recovery Scenario - Short term, Midterm and Long Term Impact

7. Global Dermatophytic Onychomycosis Therapeutics Market - Pricing Analysis

7.1. Regional Pricing Analysis By Product
7.2. Pricing Break-up
- 7.2.1. Manufacturer Level Pricing
- 7.2.2. Distributor Level Pricing
7.3. Average Pricing Analysis Benchmark

8. Global Dermatophytic Onychomycosis Therapeutics Market (Size in US$ Mn) Analysis 2013-2021 and Forecast, 2022-2031

8.1. Historical Market Value (US$ Mn) Analysis, 2013-2021
8.2. Current and Future Market Value (US$ Mn) Projections, 2022-2031
- 8.2.1. Y-o-Y Growth Trend Analysis
- 8.2.2. Absolute $ Opportunity Analysis

9. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, By Treatment

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2013-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2022-2031
- 9.3.1. Drugs
  - 9.3.1.1. Oral
    - 9.3.1.1.1. Rx
    - 9.3.1.1.2. OTC
  - 9.3.1.2. Topical
    - 9.3.1.2.1. Rx
    - 9.3.1.2.2. OTC
- 9.3.2. Lasers
  - 9.3.2.1. Neodymium: yttrium-aluminium-garnet laser (Nd:YAG)
  - 9.3.2.2. Dual-wavelength near-infrared laser
  - 9.3.2.3. CO2 Ablative Laser
- 9.3.3. Photodynamic Therapy
9.4. Market Attractiveness Analysis By Treatment

10. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Indication

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) By Indication, 2013-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2022-2031
- 10.3.1. Distal Subungual Onychomycosis
- 10.3.2. White Superficial Onychomycosis
- 10.3.3. Proximal Subungual Onychomycosis
- 10.3.4. Candida Onychomycosis
- 10.3.5. Total Dystrophic Onychomycosis
10.4. Market Attractiveness Analysis By Indication

11. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Gender

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Gender, 2013-2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Gender, 2022-2031
- 11.3.1. Male
- 11.3.2. Female
11.4. Market Attractiveness Analysis By Gender

12. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Age Group

12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Age Group, 2013-2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Age Group, 2022-2031
- 12.3.1. 0-18 Years
- 12.3.2. 18-39 Years
- 12.3.3. 40-64 Years
- 12.3.4. 65 Years and Above
12.4. Market Attractiveness Analysis By Gender

13. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Distribution Channelbr /> 13.1. Introduction / Key Findings

13.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2013-2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2031
- 13.3.1. Institutional Sales
  - 13.3.1.1. Hospitals
  - 13.3.1.2. Dermatology Clinics
- 13.3.2. Retail Sales
  - 13.3.2.1. Retail Pharmacies
  - 13.3.2.2. Drugs Stores
- 13.3.3. Mail Order Pharmacies & Online Sales
13.4. Market Attractiveness Analysis By Gender

14. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031, by Region

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Region, 2013 - 2021
14.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2031
- 14.3.1. North America
- 14.3.2. Latin America
- 14.3.3. Europe
- 14.3.4. East Asia
- 14.3.5. South Asia
- 14.3.6. Oceania
- 14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region

15. North America Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
- 15.3.1. By Country
  - 15.3.1.1. U.S.
  - 15.3.1.2. Canada
- 15.3.2. By Treatment
- 15.3.3. By Indication
- 15.3.4. By Gender
- 15.3.5. By Age group
- 15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis

16. Latin America Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
- 16.3.1. By Country
  - 16.3.1.1. Brazil
  - 16.3.1.2. Mexico
  - 16.3.1.3. Argentina
  - 16.3.1.4. Rest of Latin America
- 16.3.2. By Treatment
- 16.3.3. By Indication
- 16.3.4. By Gender
- 16.3.5. By Age group
- 16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis

17. Europe Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
- 17.3.1. By Country
  - 17.3.1.1. Germany
  - 17.3.1.2. Italy
  - 17.3.1.3. France
  - 17.3.1.4. U.K.
  - 17.3.1.5. Spain
  - 17.3.1.6. BENELUX
  - 17.3.1.7. Russia
  - 17.3.1.8. Rest of Europe
- 17.3.2. By Treatment
- 17.3.3. By Indication
- 17.3.4. By Gender
- 17.3.5. By Age group
- 17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis

18. South Asia Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
- 18.3.1. By Country
  - 18.3.1.1. India
  - 18.3.1.2. Thailand
  - 18.3.1.3. Indonesia
  - 18.3.1.4. Malaysia
  - 18.3.1.5. Rest of South Asia
- 18.3.2. By Treatment
- 18.3.3. By Indication
- 18.3.4. By Gender
- 18.3.5. By Age group
- 18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis

19. Oceania Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
- 19.3.1. By Country
  - 19.3.1.1. Australia
  - 19.3.1.2. New Zealand
- 19.3.2. By Treatment
- 19.3.3. By Indication
- 19.3.4. By Gender
- 19.3.5. By Age group
- 19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Dermatophytic Onychomycosis Therapeutics Market Analysis 2013-2021 and Forecast 2022-2031

20.1. Introduction
20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2013-2021
20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2031
- 20.3.1. By Country
  - 20.3.1.1. GCC Countries
  - 20.3.1.2. Turkey
  - 20.3.1.3. South Africa
  - 20.3.1.4. Rest of Middle East and Africa
- 20.3.2. By Treatment
- 20.3.3. By Indication
- 20.3.4. By Gender
- 20.3.5. By Age group
- 20.3.6. By Distribution Channel
20.4. Market Attractiveness Analysis
20.5. Key Market Participants - Intensity Mapping
20.6. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Dermatophytic Onychomycosis Therapeutics Market Analysis 2022 & 2031

21.1. Introduction
- 21.1.1. Market Value Proportion Analysis, By Key Countries
- 21.1.2. Global Vs. Country Growth Comparison
21.2. U.S. Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.2.1. By Treatment
- 21.2.2. By Indication
- 21.2.3. By Gender
- 21.2.4. By Age group
- 21.2.5. By Distribution Channel
21.3. Canada Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.3.1. By Treatment
- 21.3.2. By Indication
- 21.3.3. By Gender
- 21.3.4. By Age group
- 21.3.5. By Distribution Channel
21.4. Brazil Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.4.1. By Treatment
- 21.4.2. By Indication
- 21.4.3. By Gender
- 21.4.4. By Age group
- 21.4.5. By Distribution Channel
21.5. Mexico Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.5.1. By Treatment
- 21.5.2. By Indication
- 21.5.3. By Gender
- 21.5.4. By Age group
- 21.5.5. By Distribution Channel
21.6. Argentina Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.6.1. By Treatment
- 21.6.2. By Indication
- 21.6.3. By Gender
- 21.6.4. By Age group
- 21.6.5. By Distribution Channel
21.7. Germany Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.7.1. By Treatment
- 21.7.2. By Indication
- 21.7.3. By Gender
- 21.7.4. By Age group
- 21.7.5. By Distribution Channel
21.8. France Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.8.1. By Treatment
- 21.8.2. By Indication
- 21.8.3. By Gender
- 21.8.4. By Age group
- 21.8.5. By Distribution Channel
21.9. U.K. Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.9.1. By Treatment
- 21.9.2. By Indication
- 21.9.3. By Gender
- 21.9.4. By Age group
- 21.9.5. By Distribution Channel
21.10. Spain Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.10.1. By Treatment
- 21.10.2. By Indication
- 21.10.3. By Gender
- 21.10.4. By Age group
- 21.10.5. By Distribution Channel
21.11. BENELUX Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.11.1. By Treatment
- 21.11.2. By Indication
- 21.11.3. By Gender
- 21.11.4. By Age group
- 21.11.5. By Distribution Channel
21.12. Russia Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.12.1. By Treatment
- 21.12.2. By Indication
- 21.12.3. By Gender
- 21.12.4. By Age group
- 21.12.5. By Distribution Channel
21.13. India Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.13.1. By Treatment
- 21.13.2. By Indication
- 21.13.3. By Gender
- 21.13.4. By Age group
- 21.13.5. By Distribution Channel
21.14. Thailand Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.14.1. By Treatment
- 21.14.2. By Indication
- 21.14.3. By Gender
- 21.14.4. By Age group
- 21.14.5. By Distribution Channel
21.15. Indonesia Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.15.1. By Treatment
- 21.15.2. By Indication
- 21.15.3. By Gender
- 21.15.4. By Age group
- 21.15.5. By Distribution Channel
21.16. Malaysia Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.16.1. By Treatment
- 21.16.2. By Indication
- 21.16.3. By Gender
- 21.16.4. By Age group
- 21.16.5. By Distribution Channel
21.17. ASEAN Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.17.1. By Treatment
- 21.17.2. By Indication
- 21.17.3. By Gender
- 21.17.4. By Age group
- 21.17.5. By Distribution Channel
21.18. China Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.18.1. By Treatment
- 21.18.2. By Indication
- 21.18.3. By Gender
- 21.18.4. By Age group
- 21.18.5. By Distribution Channel
21.19. Japan Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.19.1. By Treatment
- 21.19.2. By Indication
- 21.19.3. By Gender
- 21.19.4. By Age group
- 21.19.5. By Distribution Channel
21.20. South Korea Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.20.1. By Treatment
- 21.20.2. By Indication
- 21.20.3. By Gender
- 21.20.4. By Age group
- 21.20.5. By Distribution Channel
21.21. Australia Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.21.1. By Treatment
- 21.21.2. By Indication
- 21.21.3. By Gender
- 21.21.4. By Age group
- 21.21.5. By Distribution Channel
21.22. New Zealand Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.22.1. By Treatment
- 21.22.2. By Indication
- 21.22.3. By Gender
- 21.22.4. By Age group
- 21.22.5. By Distribution Channel
21.23. GCC Countries Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.23.1. By Treatment
- 21.23.2. By Indication
- 21.23.3. By Gender
- 21.23.4. By Age group
- 21.23.5. By Distribution Channel
21.24. South Africa Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.24.1. By Treatment
- 21.24.2. By Indication
- 21.24.3. By Gender
- 21.24.4. By Age group
- 21.24.5. By Distribution Channel

22. Market Structure Analysis

22.1. Market Analysis by Tier of Companies
22.2. Market Concentration
22.3. Market Share Analysis of Top Players
22.4. Market Presence Analysis
- 22.4.1. By Regional footprint of Players
- 22.4.2. Product foot print by Players
- 22.4.3. Channel Foot Print by Players

23. Competition Analysis

23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
- 23.3.1. Bausch Health
  - 23.3.1.1. Overview
  - 23.3.1.2. Product Portfolio
  - 23.3.1.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.1.4. Sales Footprint
  - 23.3.1.5. Strategy Overview
    - 23.3.1.5.1. Marketing Strategy
    - 23.3.1.5.2. Product Strategy
    - 23.3.1.5.3. Channel Strategy
- 23.3.2. Galderma S.A.
  - 23.3.2.1. Overview
  - 23.3.2.2. Product Portfolio
  - 23.3.2.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.2.4. Sales Footprint
  - 23.3.2.5. Strategy Overview
    - 23.3.2.5.1. Marketing Strategy
    - 23.3.2.5.2. Product Strategy
    - 23.3.2.5.3. Channel Strategy
- 23.3.3. Novartis AG
  - 23.3.3.1. Overview
  - 23.3.3.2. Product Portfolio
  - 23.3.3.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.3.4. Sales Footprint
  - 23.3.3.5. Strategy Overview
    - 23.3.3.5.1. Marketing Strategy
    - 23.3.3.5.2. Product Strategy
    - 23.3.3.5.3. Channel Strategy
- 23.3.4. Pfizer, Inc.
  - 23.3.4.1. Overview
  - 23.3.4.2. Product Portfolio
  - 23.3.4.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.4.4. Sales Footprint
  - 23.3.4.5. Strategy Overview
    - 23.3.4.5.1. Marketing Strategy
    - 23.3.4.5.2. Product Strategy
    - 23.3.4.5.3. Channel Strategy
- 23.3.5. Moberg Pharma AB
  - 23.3.5.1. Overview
  - 23.3.5.2. Product Portfolio
  - 23.3.5.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.5.4. Sales Footprint
  - 23.3.5.5. Strategy Overview
    - 23.3.5.5.1. Marketing Strategy
    - 23.3.5.5.2. Product Strategy
    - 23.3.5.5.3. Channel Strategy
- 23.3.6. Bayer AG
  - 23.3.6.1. Overview
  - 23.3.6.2. Product Portfolio
  - 23.3.6.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.6.4. Sales Footprint
  - 23.3.6.5. Strategy Overview
    - 23.3.6.5.1. Marketing Strategy
    - 23.3.6.5.2. Product Strategy
    - 23.3.6.5.3. Channel Strategy
- 23.3.7. Dr. Reddy's Laboratories Ltd.
  - 23.3.7.1. Overview
  - 23.3.7.2. Product Portfolio
  - 23.3.7.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.7.4. Sales Footprint
  - 23.3.7.5. Strategy Overview
    - 23.3.7.5.1. Marketing Strategy
    - 23.3.7.5.2. Product Strategy
    - 23.3.7.5.3. Channel Strategy
- 23.3.8. Cipla Ltd.
  - 23.3.8.1. Overview
  - 23.3.8.2. Product Portfolio
  - 23.3.8.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.8.4. Sales Footprint
  - 23.3.8.5. Strategy Overview
    - 23.3.8.5.1. Marketing Strategy
    - 23.3.8.5.2. Product Strategy
    - 23.3.8.5.3. Channel Strategy
- 23.3.9. Medimetriks Pharmaceuticals, Inc.
  - 23.3.9.1. Overview
  - 23.3.9.2. Product Portfolio
  - 23.3.9.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.9.4. Sales Footprint
  - 23.3.9.5. Strategy Overview
    - 23.3.9.5.1. Marketing Strategy
    - 23.3.9.5.2. Product Strategy
    - 23.3.9.5.3. Channel Strategy
- 23.3.10. Sanofi S.A.
  - 23.3.10.1. Overview
  - 23.3.10.2. Product Portfolio
  - 23.3.10.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.10.4. Sales Footprint
  - 23.3.10.5. Strategy Overview
    - 23.3.10.5.1. Marketing Strategy
    - 23.3.10.5.2. Product Strategy
    - 23.3.10.5.3. Channel Strategy
- 23.3.11. GlaxoSmithKline Plc.
  - 23.3.11.1. Overview
  - 23.3.11.2. Product Portfolio
  - 23.3.11.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.11.4. Sales Footprint
  - 23.3.11.5. Strategy Overview
    - 23.3.11.5.1. Marketing Strategy
    - 23.3.11.5.2. Product Strategy
    - 23.3.11.5.3. Channel Strategy
- 23.3.12. Teva Pharmaceutical industries Ltd.
  - 23.3.12.1. Overview
  - 23.3.12.2. Product Portfolio
  - 23.3.12.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.12.4. Sales Footprint
  - 23.3.12.5. Strategy Overview
    - 23.3.12.5.1. Marketing Strategy
    - 23.3.12.5.2. Product Strategy
    - 23.3.12.5.3. Channel Strategy
- 23.3.13. Cardinal Health Inc.
  - 23.3.13.1. Overview
  - 23.3.13.2. Product Portfolio
  - 23.3.13.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.13.4. Sales Footprint
  - 23.3.13.5. Strategy Overview
    - 23.3.13.5.1. Marketing Strategy
    - 23.3.13.5.2. Product Strategy
    - 23.3.13.5.3. Channel Strategy
- 23.3.14. Viatris Inc.
  - 23.3.14.1. Overview
  - 23.3.14.2. Product Portfolio
  - 23.3.14.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.14.4. Sales Footprint
  - 23.3.14.5. Strategy Overview
    - 23.3.14.5.1. Marketing Strategy
    - 23.3.14.5.2. Product Strategy
    - 23.3.14.5.3. Channel Strategy
- 23.3.15. Almirall, S.A
  - 23.3.15.1. Overview
  - 23.3.15.2. Product Portfolio
  - 23.3.15.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.15.4. Sales Footprint
  - 23.3.15.5. Strategy Overview
    - 23.3.15.5.1. Marketing Strategy
    - 23.3.15.5.2. Product Strategy
    - 23.3.15.5.3. Channel Strategy

皮膚糸状菌性爪真菌症治療薬市場：北米が世界市場シェアの50%近くを占める見込み

Market Study on Dermatophytic Onychomycosis Therapeutics: North America to Account for Close to 50% Global Market Share

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 主要な市場動向

第4章 主要な成功要因

第5章 市場の背景

第6章 COVID19-影響分析

第7章 世界の皮膚糸状菌性爪真菌症治療薬市場-価格分析

第8章 世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第9章 世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：治療別

第10章 世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：適応別

第11章 世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：性別

第12章 世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：年齢層別

第13章 世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：流通チャネル別

第14章 世界の皮膚糸状菌性爪真菌症治療薬市場の分析と予測：地域別

第15章 北米の皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第16章 ラテンアメリカの皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第17章 欧州の皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第18章 南アジアの皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第19章 オセアニアの皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第20章 中東・アフリカの皮膚糸状菌性爪真菌症治療薬市場の分析と予測

第21章 主要および新興国の皮膚糸状菌性爪真菌症治療薬市場分析：2022年および2031年

第22章 市場構造分析

第23章 競合分析

第24章 使用される仮定と頭字語

第25章 調査手法